Search

Author/Creator Danese, S

31. DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial. (15th January 2020)

Authors:
Fiorino, G; Allocca, M; Gilardi, D; Alfieri, M; Danieli, P; Furfaro, F; Roda, G; Loy, L; Zilli, A; Radice, S; Peyrin-Biroulet, L; Danese, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 14(2020)Supplement 1
Page Start:
S102
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

32. DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study. (15th January 2020)

Authors:
Danese, S; Klopocka, M; Scherl, E J; Romatowski, J; Allegretti, J R; Peeva, E; Vincent, M S; Schoenbeck, U; Xi, L; Ye, Z; Hassan-Zahraee, M; Rath, N; Li, G; Neelakantan, S; Banfield, C; Lepsy, C; Chandra, D; Hung, K E
Journal:
Journal of Crohn's and colitis
Issue:
Volume 14(2020)Supplement 1
Page Start:
S108
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

33. DOP73 A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis. (21st January 2022)

Authors:
Peyrin-Biroulet, L; Arkkila, P; Armuzzi, A; Atreya, R; Danese, S; Ferrante, M; Guardiola, J; Jahnsen, J; Louis, E; Lukáš, M; Reinisch, W; Roblin, X; Smith, P J; Kwon, T S; Kim, J Y; Yoon, S W; Kim, D H
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i116
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

34. DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study. (15th January 2020)

Authors:
Sands, B E; Moss, A C; Armuzzi, A; Marshall, J K; Lindsay, J O; Sandborn, W J; Danese, S; Zeroncio, M; Modesto, I; Salese, L; Lawendy, N; Zhang, H; Su, C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 14(2020)Supplement 1
Page Start:
S110
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

35. DOP76 Corticosteroid sparing effects of ustekinumab therapy for ulcerative colitis through 2 years: UNIFI long-term extension. (15th January 2020)

Authors:
Peyrin-Biroulet, L; Sandborn, W; Sands, B; Scherl, E; Marano, C; O'Brien, C; Zhang, H; Johanns, J; Zhou, Y; Abreu, M; Arasaradnam, R P; Rowbotham, D S; Leong, R W L; Danese, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 14(2020)Supplement 1
Page Start:
S113
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

36. DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition in Ulcerative Colitis (UC) (Phase 2b Vibrato study). (21st January 2022)

Authors:
Hassan-Zahraee PhD, M; Ye, Z; Xi, L; Banerjee, A; He, W; Dushin, E; Lee, J; Altintas, E; Romatowski, J; Leszczyszyn, J; Danese, S; Sandborn, W J; Banfield, C; Gale, J; Peeva, E; Vincent, M; Hyde, C; Longman, R; Hung, K E
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i124
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

37. DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. (27th May 2021)

Authors:
Abreu, M T; Danese, S; Sandborn, W J; Miao, Y; Tikhonov, I; Zhang, H; Panaccione, R; Hisamatsu, T; Scherl, E J; Leong, R W; Rowbotham, D S; Arasaradnam, R P; Afif, W; Peyrin-Biroulet, L; Sands, B E; Marano, C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S113
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

38. DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn's Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study. (27th May 2021)

Authors:
D'Haens, G; Baert, F; Danese, S; Kobayashi, T; Loftus, E V; Sandborn, W J; Dornic, Q; Lindner, D; Kisfalvi, K; Marins, E G; Vermeire, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

39. DOP86 Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension. (27th May 2021)

Authors:
Scherl, E J; Rowbotham, D S; Danese, S; Sandborn, W J; Miao, Y; Zhang, H; Abreu, M T; Panaccione, R; Afif, W; Hisamatsu, T; Leong, R W; Arasaradnam, R P; Sands, B E; Marano, C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S117
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

40. DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD). (30th January 2023)

Authors:
Colombel, J F; Hanauer, S B; Sandborn, W; Sands, B E; Schreiber, S; Danese, S; Kierkus, J; Kulynych, R; Klopocka, M; Lahat, A; Gonciarz, M; Osipenko, M; Borzan, V; Kowalski, M; Saenko, D; Sardinov, R; Kim, S; Bae, Y; Lee, S; Yang, S
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i161
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗